Zacks
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
➖
AI Sentiment
Neutral
5/10
- Home
- ACAD
as of 12-03-2025 3:43pm EST
$25.98
+$0.55
+2.14%
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Chart Type:
Time Range:
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.2B | IPO Year: | 2004 |
| Target Price: | $29.24 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.54 | EPS Growth: | 98.53 |
| 52 Week Low/High: | $13.40 - $26.65 | Next Earning Date: | 11-05-2025 |
| Revenue: | $1,047,118,000 | Revenue Growth: | 12.69% |
| Revenue Growth (this year): | 15.16% | Revenue Growth (next year): | 11.42% |
AI-Powered ACAD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.47%
76.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
Kihara James
Sell
PRINCIPAL ACCOUNTING OFFICER
ACAD Nov 18, 2025
Avg Cost/Share
$23.69
Shares
4,084
Total Value
$96,753.64
Owned After
25,058
SEC Form 4
Schneyer Mark C.
Sell
EVP, CHIEF FINANCIAL OFFICER
ACAD Nov 18, 2025
Avg Cost/Share
$23.69
Shares
10,262
Total Value
$243,113.96
Owned After
53,338
SEC Form 4
Daly James M
Sell
Director
ACAD Nov 10, 2025
Avg Cost/Share
$22.37
Shares
30,000
Total Value
$670,983.00
Owned After
4,041
SEC Form 4
Schneyer Mark C.
Sell
EVP, CHIEF FINANCIAL OFFICER
ACAD Sep 15, 2025
Avg Cost/Share
$23.65
Shares
3,498
Total Value
$82,727.70
Owned After
53,338
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Nov 18, 2025 | Sell | $23.69 | 4,084 | $96,753.64 | 25,058 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Nov 18, 2025 | Sell | $23.69 | 10,262 | $243,113.96 | 53,338 | |
| Daly James M | ACAD | Director | Nov 10, 2025 | Sell | $22.37 | 30,000 | $670,983.00 | 4,041 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Sep 15, 2025 | Sell | $23.65 | 3,498 | $82,727.70 | 53,338 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Compare ACAD vs Leading Stocks
See how ACAD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.